PL1696958T3 - Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej - Google Patents
Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowejInfo
- Publication number
- PL1696958T3 PL1696958T3 PL04814825T PL04814825T PL1696958T3 PL 1696958 T3 PL1696958 T3 PL 1696958T3 PL 04814825 T PL04814825 T PL 04814825T PL 04814825 T PL04814825 T PL 04814825T PL 1696958 T3 PL1696958 T3 PL 1696958T3
- Authority
- PL
- Poland
- Prior art keywords
- agents
- optic neuropathy
- nrf2
- metabolites
- glaucomatous retinopathy
- Prior art date
Links
- 206010061323 Optic neuropathy Diseases 0.000 title abstract 2
- 208000017442 Retinal disease Diseases 0.000 title abstract 2
- 206010038923 Retinopathy Diseases 0.000 title abstract 2
- 208000020911 optic nerve disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 abstract 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000004258 Ethoxyquin Substances 0.000 abstract 1
- 238000006845 Michael addition reaction Methods 0.000 abstract 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 239000012039 electrophile Substances 0.000 abstract 1
- 235000019285 ethoxyquin Nutrition 0.000 abstract 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940093500 ethoxyquin Drugs 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 150000002540 isothiocyanates Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005937 nuclear translocation Effects 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 239000002676 xenobiotic agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53177003P | 2003-12-22 | 2003-12-22 | |
| EP04814825A EP1696958B1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| PCT/US2004/042687 WO2005063295A1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1696958T3 true PL1696958T3 (pl) | 2007-08-31 |
Family
ID=34738696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04814825T PL1696958T3 (pl) | 2003-12-22 | 2004-12-17 | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
| PL07105047T PL1803468T3 (pl) | 2003-12-22 | 2004-12-17 | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07105047T PL1803468T3 (pl) | 2003-12-22 | 2004-12-17 | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050137146A1 (enExample) |
| EP (2) | EP1803468B1 (enExample) |
| JP (2) | JP4755599B2 (enExample) |
| KR (1) | KR20060127043A (enExample) |
| CN (1) | CN1897972A (enExample) |
| AT (2) | ATE523208T1 (enExample) |
| AU (1) | AU2004308919B2 (enExample) |
| BR (1) | BRPI0417987A (enExample) |
| CA (1) | CA2547852A1 (enExample) |
| CY (2) | CY1106623T1 (enExample) |
| DE (1) | DE602004005617T2 (enExample) |
| DK (2) | DK1803468T3 (enExample) |
| ES (2) | ES2282926T3 (enExample) |
| MX (1) | MXPA06006980A (enExample) |
| PL (2) | PL1696958T3 (enExample) |
| PT (2) | PT1803468E (enExample) |
| SI (2) | SI1803468T1 (enExample) |
| WO (1) | WO2005063295A1 (enExample) |
| ZA (1) | ZA200604862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
| EP1803468B1 (en) * | 2003-12-22 | 2011-09-07 | Novartis AG | Agents for treatment of glaucomatours retinopathy and optic neuropathy |
| US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| WO2006030907A1 (ja) * | 2004-09-16 | 2006-03-23 | Redox Bioscience Inc. | 網膜保護剤 |
| US20070156079A1 (en) * | 2005-09-16 | 2007-07-05 | Bg Implant, Inc. | Glaucoma Treatment Devices and Methods |
| WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2010505958A (ja) * | 2006-10-10 | 2010-02-25 | バーンハム インスティトゥート フォー メディカル リサーチ | 神経防護作用組成物および方法 |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| AU2009237579C1 (en) | 2008-04-18 | 2016-05-12 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| CN103588678A (zh) | 2008-04-18 | 2014-02-19 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
| JP5588966B2 (ja) | 2008-04-18 | 2014-09-10 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７同族体化オレアノール酸誘導体 |
| TWI558724B (zh) | 2010-04-12 | 2016-11-21 | 瑞塔醫藥有限責任公司 | 利用抗氧化發炎調節劑治療肥胖之方法 |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| WO2012009171A2 (en) * | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| RU2447864C1 (ru) * | 2010-09-15 | 2012-04-20 | Инна Витальевна Щербинина | Способ лечения заболеваний зрительного нерва и сетчатки |
| MX2014000113A (es) * | 2011-06-21 | 2015-04-13 | Univ Johns Hopkins | Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. |
| RU2546019C2 (ru) * | 2013-03-02 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения глаукомной оптической нейропатии |
| JP6340673B2 (ja) | 2013-05-02 | 2018-06-13 | レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ | 二層型眼用インプラント |
| JP7030516B2 (ja) | 2014-12-31 | 2022-03-07 | マイクロオプティクス インコーポレイテッド | 緑内障治療装置および方法 |
| JP6892693B2 (ja) | 2015-09-30 | 2021-06-23 | マイクロオプティクス インコーポレイテッド | ドライアイ治療装置および方法 |
| AU2017322544B2 (en) | 2016-09-12 | 2022-06-02 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| KR102658015B1 (ko) | 2016-09-12 | 2024-05-21 | 에스티 아이피 홀딩 아게 | 4-메틸-5-(피라진-2-일)-3h-1,2-디티올-3-티온의 제제, 및 그의 제조 및 사용 방법 |
| CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| RU2647324C1 (ru) * | 2017-04-24 | 2018-03-15 | Игорь Евгеньевич Хаценко | Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата |
| JP2023528139A (ja) * | 2020-03-30 | 2023-07-04 | ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー | ヒト核因子ｅ２関連因子２の発現ベクター及び発現ベクターの適用 |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| AU689036B2 (en) * | 1995-05-10 | 1998-03-19 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition containing substance inhibiting HSP47 production |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| WO1997023222A1 (en) * | 1995-12-21 | 1997-07-03 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| ATE247090T1 (de) * | 1996-02-02 | 2003-08-15 | Hidaka Hiroyoshi Dr | Isochinolinderivate und arzneimittel |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| JP3872834B2 (ja) * | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
| IL128456A0 (en) * | 1996-08-12 | 2000-01-31 | Yoshitomi Pharmaceutical | Compositions containing a Rho kinase inhibitor |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| US5972923A (en) * | 1997-01-16 | 1999-10-26 | University Of Florida Research Foundation, Inc. | Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| AU2440599A (en) * | 1998-02-25 | 1999-09-15 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| CA2357265C (en) * | 2001-04-24 | 2004-04-13 | University Of British Columbia | Improved additive for livestock feeds |
| US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| AU2002357311A1 (en) * | 2001-12-18 | 2003-06-30 | Johns Hopkins University School Of Medicine | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| AU2003205737A1 (en) * | 2002-02-15 | 2003-09-04 | Humboldt Universitaet | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| AU2003263988A1 (en) * | 2002-08-05 | 2004-02-23 | Wackvom, Ltd. | Methods and compositions to treat conditions associated with neovascularization |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| BRPI0417996A (pt) * | 2003-12-22 | 2007-04-27 | Alcon Inc | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular |
| EP1803468B1 (en) * | 2003-12-22 | 2011-09-07 | Novartis AG | Agents for treatment of glaucomatours retinopathy and optic neuropathy |
-
2004
- 2004-12-17 EP EP07105047A patent/EP1803468B1/en not_active Expired - Lifetime
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 EP EP04814825A patent/EP1696958B1/en not_active Expired - Lifetime
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en not_active Ceased
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Ceased
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es not_active Expired - Lifetime
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de not_active Expired - Lifetime
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es not_active Expired - Lifetime
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
-
2007
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
-
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
-
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1696958T3 (pl) | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej | |
| PT762837E (pt) | Processo para melhorar a durabilidade e/ou estabilizacao de produtos degradaveis microbiologicamente | |
| ATE505201T1 (de) | Enzymbehandlung von nahrungsmitteln für zöliakie- sprue | |
| CY1107181T1 (el) | Συνδυασμος ζιζανιοκτονων με ακυλιωμενες αμινοφαινυλοσουλφονυλουριες | |
| NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
| ATE280758T1 (de) | Mittel zum schutz von nervenzellen | |
| EP1719410A4 (en) | METHOD FOR COMBATING PLANT HEALTH DAMAGE THROUGH THE USE OF BACILLUS AND A COMBUSTION AGENT | |
| DE602004008105D1 (de) | 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen | |
| BR0014214A (pt) | Imidazoquinolinas substituìdas com amida | |
| BRPI0417996A (pt) | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular | |
| NO20033664L (no) | Mikroorganisme for biologisk detoksifisering av mykotoksiner, dvs okratoksiner og/eller zearleoner, så vel som fremgangsmåte og anvendelsederav | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| NO20052359D0 (no) | Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser | |
| AR032548A1 (es) | Metodo y composicion para desinfectar una superficie contaminada con una proteina prion | |
| WO2005048920A3 (en) | Methods and compositions for protecting against cataract development associated with vitrectomies | |
| EP1478660A4 (en) | KAPPA-PVIIA-RELATED CONOTOXINS AS ORGAN PROTECTIVE AGENTS | |
| BR0313186A (pt) | Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol | |
| ES2126795T3 (es) | Formulacion y procedimiento de control de los nematodos parasitos de las plantas. | |
| ES2036238T3 (es) | Derivados de hidroxietil-azolilo. | |
| ES2062570T3 (es) | L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias. | |
| ATE526992T1 (de) | Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung | |
| GT200000136A (es) | Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2 : b1 (2). | |
| BR0215752A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
| BR0313543A (pt) | 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b | |
| ES2093054T3 (es) | Antibioticos ab-023 y procedimiento para su preparacion. |